18889881171
Kalkine 0
countryflagUS

ALK-Abelló A/S

Healthcare US AKBLF

26.99USD
-(-%)

Last update at 2025-06-12T13:30:00Z

Day Range

26.9926.99
LowHigh

52 Week Range

13.2527.03
LowHigh

Fundamentals

  • Previous Close 26.99
  • Market Cap5089.10M
  • Volume0
  • P/E Ratio44.10
  • Dividend Yield-%
  • EBITDA1102.00M
  • Revenue TTM5180.00M
  • Revenue Per Share TTM21.81
  • Gross Profit TTM 2822.00M
  • Diluted EPS TTM0.50

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax 647.00M 447.00M 279.00M 101.00M -31.00000M
Minority interest - - - - 0.00000M
Net income 486.00M 335.00M 219.00M 25.00M -50.00000M
Selling general administrative 331.00M 276.00M 240.00M 237.00M 246.00M
Selling and marketing expenses 1422.00M 1381.00M 1234.00M 1125.00M 1210.00M
Gross profit 3035.00M 2791.00M 2396.00M 2028.00M 1892.00M
Reconciled depreciation 245.00M 238.00M 242.00M 245.00M 255.00M
Ebit 669.00M 473.00M 322.00M 104.00M -7.00000M
Ebitda 913.00M 709.00M 544.00M 311.00M 248.00M
Depreciation and amortization 244.00M 236.00M 222.00M 207.00M 255.00M
Non operating income net other - - - - 0.00000M
Operating income 666.00M 470.00M 292.00M 150.00M -14.00000M
Other operating expenses 4158.00M 4041.00M 3624.00M 3340.00M 3304.00M
Interest expense 22.00M 24.00M 23.00M 34.00M 34.00M
Tax provision 161.00M 112.00M 60.00M 76.00M 19.00M
Interest income 12.00M 4.00M 1.00M 5.00M 17.00M
Net interest income -10.00000M -20.00000M -22.00000M -29.00000M -17.00000M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 161.00M 112.00M 60.00M 76.00M 19.00M
Total revenue 4824.00M 4511.00M 3916.00M 3491.00M 3274.00M
Total operating expenses 2369.00M 2321.00M 2104.00M 1877.00M 1922.00M
Cost of revenue 1789.00M 1720.00M 1520.00M 1463.00M 1382.00M
Total other income expense net -19.00000M -23.00000M -13.00000M -49.00000M -17.00000M
Discontinued operations - - - - 0.00000M
Net income from continuing ops 486.00M 335.00M 219.00M 25.00M -50.00000M
Net income applicable to common shares - 335.00M 219.00M 25.00M -50.00000M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 6726.00M 6308.00M 5830.00M 5563.00M 5495.00M
Intangible assets 212.00M 182.00M 165.00M 172.00M 221.00M
Earning assets - - - - -
Other current assets 255.00M - - - 0.00000M
Total liab 2279.00M 2320.00M 2350.00M 2410.00M 2319.00M
Total stockholder equity 4447.00M 3988.00M 3480.00M 3153.00M 3176.00M
Deferred long term liab - - - - 0.00000M
Other current liab 747.00M 1001.00M 989.00M 905.00M 804.00M
Common stock 111.00M 111.00M 111.00M 111.00M 111.00M
Capital stock 111.00M 111.00M 111.00M 111.00M 111.00M
Retained earnings 4354.00M 3857.00M 3410.00M 3167.00M 3084.00M
Other liab - 492.00M 536.00M 488.00M 444.00M
Good will 459.00M 460.00M 457.00M 452.00M 461.00M
Other assets - 1003.00M 991.00M 895.00M 826.00M
Cash 474.00M 221.00M 194.00M 298.00M 316.00M
Cash and equivalents - - - - -
Total current liabilities 1314.00M 1399.00M 1385.00M 1029.00M 934.00M
Current deferred revenue 4.00M - - - -
Net debt 291.00M 475.00M 516.00M 645.00M 674.00M
Short term debt 326.00M 267.00M 281.00M 50.00M 49.00M
Short long term debt 280.00M 226.00M 244.00M 18.00M 18.00M
Short long term debt total 765.00M 696.00M 710.00M 943.00M 990.00M
Other stockholder equity -36.00000M 20.00M -41.00000M -125.00000M -19.00000M
Property plant equipment - 2018.00M 1814.00M 1704.00M 1739.00M
Total current assets 2968.00M 2645.00M 2403.00M 2340.00M 2248.00M
Long term investments - - - - 0.00000M
Net tangible assets - 3346.00M 2858.00M 2529.00M 2494.00M
Short term investments - - - - 0.00000M
Net receivables 816.00M 764.00M 691.00M 684.00M 665.00M
Long term debt 184.00M 203.00M 222.00M 686.00M 707.00M
Inventory 1423.00M 1297.00M 1204.00M 1093.00M 1056.00M
Accounts payable 128.00M 131.00M 115.00M 74.00M 81.00M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income -18.00000M - - - 0.00000M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - - 0.00000M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 906.00M 287.00M 201.00M 198.00M 206.00M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 3758.00M 3663.00M 3427.00M 3223.00M 3247.00M
Capital lease obligations 301.00M 267.00M 244.00M 239.00M 265.00M
Long term debt total - - - - 0.00000M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -375.00000M -351.00000M -3.00000M -23.00000M 1.00M
Change to liabilities - 11.00M 61.00M 74.00M 159.00M
Total cashflows from investing activities - -351.00000M -266.00000M -245.00000M -157.00000M
Net borrowings - -73.00000M -270.00000M -49.00000M -44.00000M
Total cash from financing activities -31.00000M -42.00000M -311.00000M -62.00000M -57.00000M
Change to operating activities - - - -154.00000M -154.00000M
Net income 486.00M 335.00M 219.00M 25.00M -50.00000M
Change in cash 253.00M 27.00M -104.00000M -18.00000M -80.00000M
Begin period cash flow 221.00M 194.00M 298.00M 316.00M 396.00M
End period cash flow 474.00M 221.00M 194.00M 298.00M 316.00M
Total cash from operating activities 667.00M 416.00M 468.00M 301.00M 132.00M
Issuance of capital stock -20.00000M 31.00M 41.00M 13.00M 13.00M
Depreciation 244.00M 238.00M 242.00M 245.00M 255.00M
Other cashflows from investing activities - - - - 0.00000M
Dividends paid - - - 24.00M 24.00M
Change to inventory -132.00000M -74.00000M -84.00000M -69.00000M -54.00000M
Change to account receivables -69.00000M -172.00000M -5.00000M -159.00000M -200.00000M
Sale purchase of stock - - - -24.00000M -24.00000M
Other cashflows from financing activities -46.00000M -351.00000M -266.00000M -13.00000M -13.00000M
Change to netincome - 80.00M 55.00M 223.00M 52.00M
Capital expenditures 379.00M 353.00M 263.00M 222.00M 167.00M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -201.00000M -235.00000M -28.00000M -154.00000M -95.00000M
Stock based compensation 30.00M 27.00M 36.00M 29.00M 39.00M
Other non cash items 108.00M 29.00M 62.00M 112.00M 90.00M
Free cash flow 288.00M 63.00M 205.00M 79.00M -35.00000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AKBLF
ALK-Abelló A/S		 - -% 26.99 44.10 - 6.52 6.76 6.64 26.62
NVO
Novo Nordisk A/S		 -0.56 0.69% 80.49 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.41 0.51% 80.59 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.29 0.28% 458.77 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.82 0.54% 524.66 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.

ALK-Abelló A/S

BOege AllE 6-8, Horsholm, Denmark, 2970

Key Executives

Name Title Year Born
Mr. Carsten Hellmann Pres, CEO & Member of Management Board 1964
Mr. Soren Jelert Group CFO, Exec. VP & Member of Management Board 1972
Mr. Henrik Jacobi Exec. VP of R&D and Member of Board of Management 1965
Mr. Søren Daniel Niegel Exec. VP of Commercial Operations & Member of Management Board 1971
Ms. Katja Barnkob Thalund Project Director of Global CMC Devel. & Employee-elected Director 1969
Mr. Per Plotnikof VP of Corp. Communications, Investor Relations & Strategic Planning and Head of IR NA
Prof. Hendrik Kees Kam Nolte M.D., Ph.D. Sr. VP of Research & Devel. - North America and International Markets NA
Mr. Christian G. Houghton Head of Product Supply NA
Mr. Miles Guralnick Pres of ALK Abelló Source Materials Inc NA
Mr. Claus Steensen Solje Executive VP, CFO & Member of Management Board 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.